

## Leon Chen

Founding Partner & CEO 6 Dimensions Capital

Leon Chen is one of the most productive life sciences venture capital investment professionals with extensive experience in China, North America and Europe. With decades of collective cross-border successful investment track records. Dr. Chen is the Chairman and CEO of 120 Capital, a successor fund of 6 Dimensions Capital, and CEO and Founding Managing Partner of 6DC, formed in 2017 through a merger between Frontline BioVentures with WuXi Healthcare Ventures. Prior to that, he founded Frontline BioVentures, a cross-border venture capital firm in 2012. Under Dr. Chen's leadership 6DC has grown significantly to become one of the top healthcare venture capital institutions with teams on the ground in both the U.S. and China, with over US\$1.6 billion assets under management. 6DC currently has an active portfolio of near 100 companies. Dr. Chen has over 30 years of experience in the life sciences industry as a venture capital investor, senior management executive, entrepreneur, and scientific inventor. Dr. Chen is one of the earliest Western-trained healthcare investors established in China, a pioneer of the industry when he led an investment in CITIC Pharmaceutical Co., Ltd. back in 2006. Since then, he has led/co-led investments in many notable companies including Cathay Biotech Inc., Shanghai Hile Bio-Technology Co., Ltd., Innovent Biologics, Inc., Ocumension Therapeutics, Cutia Therapeutics, Hua Medicine, CStone Pharmaceuticals, Adagene (Suzhou) Limited., Yikon Genomics Co. Ltd., TenNor Therapeutics Ltd., Coherent Biopharma (Suzhou) Co., Ltd., GKHT Medical Technology Co., Ltd., SinoHealth (Shanghai) Co. Ltd., Neusoft Medical Systems Co. Ltd., Shenzhen Kangtai Biological Products Co., Grail, Gracell, EngineBio Ltd., and 111.com. Dr. Chen has a distinct track record of identifying unmet needs, creating and seeding startups addressing the unmet needs, building management teams and helping the companies to become unicorns. Some of these landmark investments include: Innovent Biologics, Occumension Therapeutics, and Cutia Therapeutics. Dr. Chen conducted post-doctoral research in chemistry at the Massachusetts Institute of Technology. He obtained his Ph.D. in chemistry (with top honor) from the University of Louvain, Belgium. He graduated from Peking University majoring in chemistry in China.